Drug Trial Radar · NCT05902221
Impact of Rifampicin in Treatment Outcome of Cutibacterium Acnes Prosthetic Joint Infections
Last checked: Nov 20, 2026Latest source record: Jun 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
235
Planned (sponsor's estimate)
Start
May 2, 2024
Primary completion
May 2028
Study completion May 2028
Sponsor
- Lead sponsor
- Centre Hospitalier Universitaire de NiceAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 13, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Cutibacterium acnes is involved in nearly 40% of shoulder prosthetic joint infections (PJI). After shoulder prothesis, C. acnes mainly affects hip prosthesis. One recent work from the Lyon (France) bone and joint infections reference center with data focusing mainly on hip and knee PJI has reported that C. acnes is the leading cause of late-onset PJI after coagulase negative staphylococci (CNS) (late acute PJI not considered). In such late-onset device-related infection, biofilm, as produced by C. acnes during PJI represents a major hurdle on the path to patient's cure. Because biofilm-associated bacteria have a slower metabolism and a lower multiplication rate than planktonic bacteria, antibiotic susceptibility can be hampered. Rifampicin is an antibiotic with low minimal bactericidal concentration against S. aureus and CNS biofilm-associated bacteria8 which significantly influence patient's outcome during staphylococci PJI.
Conditions
- Infections Joint Prosthetic
Interventions
amoxicillin or moxifloxacinDrug
Antibiotic treatment back bone during 12 weeks
amoxicillin or moxifloxacin + rifampicinDrug
Antibiotic treatment back bone during 12 weeks + rifampicin
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of C. acnes prosthetic joint infections management failureTime frame: 24 months after the end of antibiotic treatment
- Rate of adverse event linked to rifampicinTime frame: during rifampicin treatment
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
CH Annecy Genevois
Annecy, France · Recruiting
CHU de BORDEAUX
Bordeaux, France · Recruiting
Hôpital Ambroise Paré
Boulogne, France · Recruiting
HCL
Lyon, France · Recruiting
AP-HM
Marseille, France · Not yet recruiting
CHU de MONTPELLIER
Montpellier, France · Recruiting
CHU de Nantes
Nantes, France · Recruiting
CHU de NICE
Nice, France · Recruiting
Dianonesses croix saint simon
Paris, France · Recruiting
CHU de Rennes
Rennes, France · Recruiting
CHU Toulouse
Toulouse, France · Recruiting
Ch Tourcoing
Tourcoing, France · Recruiting
CHRU Tours
Tours, France · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.